• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

弗雷明汉风险函数对北欧人群是否有效?高危男性绝对冠心病风险估计方法的比较。

Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men.

作者信息

Haq I U, Ramsay L E, Yeo W W, Jackson P R, Wallis E J

机构信息

Section of Clinical Pharmacology and Therapeutics, Department of Medicine and Pharmacology, University of Sheffield, Sheffield, UK.

出版信息

Heart. 1999 Jan;81(1):40-6. doi: 10.1136/hrt.81.1.40.

DOI:10.1136/hrt.81.1.40
PMID:10220543
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1728900/
Abstract

OBJECTIVE

To examine the validity of estimates of coronary heart disease (CHD) risk by the Framingham risk function, for European populations.

DESIGN

Comparison of CHD risk estimates for individuals derived from the Framingham, prospective cardiovascular Münster (PROCAM), Dundee, and British regional heart (BRHS) risk functions.

SETTING

Sheffield Hypertension Clinic. Patients-206 consecutive hypertensive men aged 35-75 years without preexisting vascular disease.

RESULTS

There was close agreement among the Framingham, PROCAM, and Dundee risk functions for average CHD risk. For individuals the best correlation was between Framingham and PROCAM, both of which use high density lipoprotein (HDL) cholesterol. When Framingham was used to target a CHD event rate > 3% per year, it identified men with mean CHD risk by PROCAM of 4.6% per year and all had CHD event risks > 1.5% per year. Men at lower risk by Framingham had a mean CHD risk by PROCAM of 1.5% per year, with 16% having a CHD event risk > 3.0% per year. BRHS risk function estimates of CHD risk were fourfold lower than those for the other three risk functions, but with moderate correlations, suggesting an important systematic error.

CONCLUSION

There is close agreement between the Framingham, PROCAM, and Dundee risk functions as regards average CHD risk, and moderate agreement for estimates within individuals. Taking PROCAM as the external standard, the Framingham function separates high and low CHD risk groups and is acceptably accurate for northern European populations, at least in men.

摘要

目的

检验弗雷明汉风险函数对欧洲人群冠心病(CHD)风险估计的有效性。

设计

比较来自弗雷明汉、明斯特前瞻性心血管研究(PROCAM)、邓迪和英国地区心脏研究(BRHS)风险函数对个体的CHD风险估计。

地点

谢菲尔德高血压诊所。患者为206名连续入选的35 - 75岁无既往血管疾病的高血压男性。

结果

弗雷明汉、PROCAM和邓迪风险函数对平均CHD风险的估计结果相近。对于个体而言,弗雷明汉和PROCAM之间的相关性最佳,二者均使用高密度脂蛋白(HDL)胆固醇。当使用弗雷明汉风险函数将每年CHD事件发生率目标设定为> 3%时,它识别出的男性按PROCAM计算的平均CHD风险为每年4.6%,且所有男性每年的CHD事件风险均> 1.5%。按弗雷明汉风险函数处于较低风险的男性,按PROCAM计算的平均CHD风险为每年1.5%,其中16%的男性每年的CHD事件风险> 3.0%。BRHS风险函数对CHD风险的估计比其他三个风险函数低四倍,但相关性中等,提示存在重要的系统误差。

结论

弗雷明汉、PROCAM和邓迪风险函数在平均CHD风险方面结果相近,对个体风险估计的一致性中等。以PROCAM作为外部标准,弗雷明汉风险函数能够区分CHD高风险和低风险组,对于北欧人群至少在男性中准确性尚可接受。

相似文献

1
Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men.弗雷明汉风险函数对北欧人群是否有效?高危男性绝对冠心病风险估计方法的比较。
Heart. 1999 Jan;81(1):40-6. doi: 10.1136/hrt.81.1.40.
2
Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study.弗雷明汉和PROCAM冠心病风险函数是否适用于不同的欧洲人群?PRIME研究。
Eur Heart J. 2003 Nov;24(21):1903-11. doi: 10.1016/j.ehj.2003.09.002.
3
Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy.冠心病一级预防现行指南比较:风险评估与降脂治疗
J Gen Intern Med. 2003 Mar;18(3):190-5. doi: 10.1046/j.1525-1497.2003.20207.x.
4
Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease.在无明显血管疾病的血脂异常患者中使用弗雷明汉方程和PROCAM方程预测冠心病风险。
Int J Clin Pract. 2007 Oct;61(10):1643-53. doi: 10.1111/j.1742-1241.2007.01527.x.
5
Coronary heart disease risk assessment in diabetes mellitus--a comparison of PROCAM and Framingham risk assessment functions.糖尿病患者的冠心病风险评估——PROCAM与弗雷明汉风险评估功能的比较
Diabet Med. 2001 May;18(5):355-9. doi: 10.1046/j.1464-5491.2001.00438.x.
6
Effect of serum lipid level change on 10-year coronary heart risk distribution estimated by means of seven different coronary risk scores during one-year treatment.血清脂质水平变化对在一年治疗期间通过七种不同冠状动脉风险评分估算的10年冠心病风险分布的影响。
Med Pregl. 2014 Jul-Aug;67(7-8):208-15.
7
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study.与中国多省队列研究相比,弗雷明汉冠心病风险评估工具对中国人群的预测价值。
JAMA. 2004 Jun 2;291(21):2591-9. doi: 10.1001/jama.291.21.2591.
8
The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease.明斯特前瞻性心血管疾病(PROCAM)研究:高血压和/或糖尿病患者中高脂血症的患病率及其与冠心病的关系。
Am Heart J. 1988 Dec;116(6 Pt 2):1713-24. doi: 10.1016/0002-8703(88)90220-7.
9
Is the Framingham coronary heart disease absolute risk function applicable to Aboriginal people?弗雷明汉冠心病绝对风险函数适用于原住民吗?
Med J Aust. 2005 Jan 17;182(2):66-9.
10
A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study.在第二次诺斯威克公园心脏研究中,比较PROCAM和弗雷明汉姆积分系统对个体冠心病风险的评估。
Atherosclerosis. 2005 Jul;181(1):93-100. doi: 10.1016/j.atherosclerosis.2004.12.026.

引用本文的文献

1
Age and sex affect deep learning prediction of cardiometabolic risk factors from retinal images.年龄和性别会影响基于视网膜图像的心血管代谢危险因素的深度学习预测。
Sci Rep. 2020 Jun 10;10(1):9432. doi: 10.1038/s41598-020-65794-4.
2
Re-calibration of coronary risk prediction: an example of the Seven Countries Study.冠状动脉风险预测的再校准:七国研究示例。
Sci Rep. 2017 Dec 14;7(1):17552. doi: 10.1038/s41598-017-17784-2.
3
A comparison of outcomes with coronary artery calcium scanning in unselected populations: the Multi-Ethnic Study of Atherosclerosis (MESA) and Heinz Nixdorf RECALL study (HNR).在未选择人群中进行冠状动脉钙扫描的结果比较:多民族动脉粥样硬化研究(MESA)和 Heinz Nixdorf 召回研究(HNR)。
J Cardiovasc Comput Tomogr. 2013 May-Jun;7(3):182-91. doi: 10.1016/j.jcct.2013.05.009. Epub 2013 Jun 13.
4
Cardiovascular risk assessment--from individual risk prediction to estimation of global risk and change in risk in the population.心血管风险评估——从个体风险预测到人群的总体风险评估和风险变化。
BMC Med. 2010 May 25;8:29. doi: 10.1186/1741-7015-8-29.
5
Outcome of coronary plaque burden: a 10-year follow-up of aggressive medical management.冠状动脉斑块负荷的结果:积极药物治疗的10年随访
Cardiovasc Ultrasound. 2010 Mar 12;8:5. doi: 10.1186/1476-7120-8-5.
6
Risk charts illustrating the 10-year risk of myocardial infarction among residents of Japanese rural communities: the JMS Cohort Study.日本农村社区居民心肌梗死10年风险的风险图表:日本医学系统合作队列研究
J Epidemiol. 2009;19(2):94-100. doi: 10.2188/jea.je20080081. Epub 2009 Mar 6.
7
Biomarkers related to aging in human populations.与人类群体衰老相关的生物标志物。
Adv Clin Chem. 2008;46:161-216. doi: 10.1016/s0065-2423(08)00405-8.
8
Cardiovascular risk after bariatric surgery for obesity.肥胖症患者接受减肥手术后的心血管风险。
Am J Cardiol. 2008 Oct 1;102(7):930-7. doi: 10.1016/j.amjcard.2008.05.040. Epub 2008 Jul 17.
9
Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians.心血管疾病风险预测模型在亚洲印度人群中的应用以及新型生物标志物与风险分层的相关性。
Vasc Health Risk Manag. 2008;4(1):199-211. doi: 10.2147/vhrm.2008.04.01.199.
10
Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population.无症状人群中单核细胞计数对未来心血管疾病预测值的计算
Vasc Health Risk Manag. 2008;4(1):177-87. doi: 10.2147/vhrm.2008.04.01.177.

本文引用的文献

1
The cost effectiveness of hypertension treatment in Sweden.瑞典高血压治疗的成本效益。
Pharmacoeconomics. 1995 Mar;7(3):242-50. doi: 10.2165/00019053-199507030-00008.
2
Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence?高血压前瞻性试验的解读:治疗指南是否准确反映了当前证据?
J Hypertens Suppl. 1996 Dec;14(5):S187-94.
3
Information needed to decide about cardiovascular treatment in primary care.基层医疗中决定心血管治疗所需的信息。
BMJ. 1997 Jan 25;314(7076):277-80. doi: 10.1136/bmj.314.7076.277.
4
Lipid-lowering for prevention of coronary heart disease: what policy now?降低血脂以预防冠心病:现在该采取什么政策?
Clin Sci (Lond). 1996 Oct;91(4):399-413. doi: 10.1042/cs0910399.
5
The Sheffield table for primary prevention of coronary heart disease: corrected.用于冠心病一级预防的谢菲尔德表:校正版。
Lancet. 1996 Nov 2;348(9036):1251. doi: 10.1016/s0140-6736(05)65536-5.
6
Using a coronary risk score for screening and intervention in general practice. British Family Heart Study.在全科医疗中使用冠心病风险评分进行筛查和干预。英国家庭心脏研究。
J Cardiovasc Risk. 1996 Jun;3(3):301-6.
7
Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table.针对冠心病一级预防的降脂药物治疗:更新后的谢菲尔德表
Lancet. 1996 Aug 10;348(9024):387-8. doi: 10.1016/s0140-6736(96)05516-x.
8
Management of raised blood pressure in New Zealand: a discussion document.新西兰高血压管理:一份讨论文件。
BMJ. 1993 Jul 10;307(6896):107-10. doi: 10.1136/bmj.307.6896.107.
9
The number needed to treat: a clinically useful measure of treatment effect.需治疗人数:一种临床实用的治疗效果衡量指标。
BMJ. 1995 Feb 18;310(6977):452-4. doi: 10.1136/bmj.310.6977.452.
10
Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.临床实践中冠心病的预防。欧洲心脏病学会、欧洲动脉粥样硬化学会和欧洲高血压学会特别工作组的建议。
Eur Heart J. 1994 Oct;15(10):1300-31. doi: 10.1093/oxfordjournals.eurheartj.a060388.